undamentalytics Newsletter
Sign in

Rani Therapeutics Holdings, Inc. balance sheet

At the end of fiscal 2025, Rani Therapeutics Holdings, Inc. had total assets of $58.6m, total liabilities of $17.1m and shareholders' equity of $33.0m. It held $18.6m in cash against $0 of debt: net cash of $18.6m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents731172764195
Receivables———0022
Total current assets7512010151305357
Total assets7912410858375961
Accounts payable1111101
Deferred revenue (current)3———075
Total current liabilities5358201311
Short-term debt1—05150—
Long-term debt202924100—
Total debt4030302500
Total liabilities833432331713
Shareholders' equity−11347371323339
Non-controlling interests and other (assets − liabilities − equity)185743713299
Net debt (negative = net cash)−69−11732421−19−5

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: ANL vs RANIBOLT vs RANIIVA vs RANIRANI vs TRDA

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Rani Therapeutics Holdings, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Rani Therapeutics Holdings, Inc.